N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=36 Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM
Disorder of Glucose Regulation
Primary: Normalization of Glucose Levels — 9; 2; 4 Participants — p=.035
N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
Phase 4 N=395 Nephropathy In Type 2 Diabetes and Cardio-renal Events
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
N/A N=62 Effects of Micronutrient (Chromium) Supplementation on Diabetes
Diabetes Mellitus, Type 1
Primary: Blood Glucose Level — 172.39; 212.85; 164.47; 191.25 mg/dL
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
N/A N=86 Behavioral Change Communication for Physical Activity Among Females With Type2 Diabetes Mellitus
Physical Inactivity · Type2 Diabetes Mellitus
Primary: Total Physical Activity Log Means and Geometric Means With Standard Deviation in Intervention and Control Groups After Intervention. — 216.07; 201.47 log calories/day…
Phase 4 N=150 Diabetes in the Elderly: Prospective Study
Diabetes · Hyperglycemia
Primary: Percent of Participants With a Mean Blood Glucose Concentration of Less Than 70 mg/dL — 28; 31 percentage of participants
N/A N=958 Gestational Diabetes Mellitus Trial (GDM)
Diabetes, Gestational
Primary: Number of Participants With Composite Neonatal Morbidity — 149; 163; 62; 55 Participants — p=0.14
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
N/A N=60 Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes
Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830
Phase 3 N=9,306 Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
Diabetes Mellitus, Type 2
Primary: Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan — 33.1; 36.8 Percentage of patients
N/A N=58 Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger
Diabetes Mellitus, Type 2
Primary: Frequency of Eating in Response to Cravings (Primary Mechanistic Outcome) — -20.39; -25.27 % of EMAs with craving related eating
N/A N=30 Model Driven Diabetes Care
Diabetes Mellitus, Type 1
Primary: Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12. — -18; -7.5 Events
Phase 4 N=48 Ketosis-Prone Diabetes Mellitus (KPDM): Metformin Versus Sitagliptin Treatment
Ketosis Prone Diabetes · Diabetes Ketoacidosis · Hyperglycemia
Primary: Length of Remission — 472; 589; 111 days
N/A N=13 Effect of the Anti-oxidant N-acetylcysteine on Beta-cell Function in Type 2 Diabetes
Type 2 Diabetes · Oxidative Stress
Primary: Fasting Urine F2 Alpha Isoprostane Levels — -0.089 ng/ml
Phase 4 N=34 Glargine Versus NPH in Patients With Chronic Kidney Disease
Type 2 Diabetes Mellitus · Chronic Kidney Disease
Primary: Difference in A1c Levels — 8.86; 8.21; 7.95; 8.44 percentage — p=0.00045
Phase 3 N=127 Vitamin D for Established Type 2 Diabetes (DDM2)
Type 2 Diabetes
Primary: Disposition Index — 0.023; 0.149 index
N/A N=40 New Patient Support Program in Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Percent of Participants With Adherence to the PDTA — 98; 98; 98 percentage of participants
Phase 3 N=251 Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=523,585 Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV
Diabetes Mellitus, Type 2
Primary: Number of Index Dates — 91634; 33238; 28211; 26192 Number of Prescriptions
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
Phase 2 N=50 Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease
Primary: Percentage Change in Liver Fat Relative to Baseline Assessed by MRI-PDFF — 13.9; 8.4 percentage change in liver fat — p=0.585
Phase 2 N=164 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Non-alcoholic Steatohepatitis
Primary: Percent Change From Baseline in Whole Liver Fat at Week 16 — -3.21; -16.12; -4.36 Percent change — p=0.0696
N/A N=25 Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL
Phase 3 N=153 Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
Gestational Diabetes Mellitus · Type 2 Diabetes Mellitus · Metabolic Syndrome
Primary: Insulin Secretion-Sensitivity Index (IS-SI) — 418.4; 333 index — p=<0.04
N/A N=57 Effect of Diabetes Mellitus on Cholesterol Metabolism
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus · Hypercholesterolemia
Primary: Changes in LDL Cholesterol — -0.83; -1.47; -0.93; -0.32 mmol/L
N/A N=48 The LoBAG Diet and Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Change in Hemoglobin A1c From Baseline to Week 12 — 6.6; 7.2 percentage